Clinical Trials Browser

Phase 2 × OTHER × Immune System Diseases × Clear all

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT04258683 2023-08-29

A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE

Phase 2 Withdrawn

Plasma cell

Cardiovascular Diseases, Hematologic Diseases, Immune System Diseases, Multiple Myeloma, Neoplasms

NCT02519816 2019-08-14

CARE

Phase 2 Unknown

17 enrolled

Immune System Diseases

NCT02627573 2019-04-05

Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT

Phase 2 Terminated

32 enrolled

MyeloidOther hematologic neoplasm

Immune System Diseases, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT02294552 2018-01-16

Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT

Phase 2 Completed

200 enrolled

LymphoidMyeloidOther hematologic neoplasm

Immune System Diseases, Leukemia, Lymphoma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03373019 2017-12-14

Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Phase 2 Unknown

63 enrolled

Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Clinical Trials

SPiReL

A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE

CARE

Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT

Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT

Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)